AI Summary & Key Takeaways
AI InsightIncreased plasma TAFI antigen levelsmight aggravate prothrombotic and thrombotic events in patients with acromegaly.
📌 3 Key Takeaways
Abstract
Background/aim: Acromegaly is associated with increased morbidity andmortality, mostly due to cardiovascular complications. Plasmathrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels are associated with coagulation/fibrinolysis and inflammation. PlasmaTAFI may play a role in arterial thrombosis in cardiovascular diseases. In this study, it was aimed to evaluate the thrombin-activatablefibrinolysis inhibitor (TAFI) antigen and homocysteine levels in patients with acromegaly and healthy control subjects.Materials and methods: Plasma TAFI antigen and homocysteine levels in 29 consecutive patients with acromegaly and 26 age-matchedhealthy control subjects were measured. All patients included in the study were in remission. The TAFIa/ai antigen in the plasmasamples was measured using a commercially available ELISA kit.Results: Routine biochemical parameters, fasting blood glucose, prolactin, thyroid stimulating hormone, total-cholesterol, low densitylipoprotein cholesterol, triglyceride, and homocysteine levels were similar in the 2 groups (P > 0.05), whereas the plasma TAFI antigenlevels were significantly elevated in the acromegalic patients (154.7 ± 94.0%) when compared with the control subjects (107.2 ± 61.6%)(P = 0.033). No significant correlation was identified by Pearson’s correlation test between the plasma TAFI antigen and homocysteinelevels (r = 0.320, P = 0.250).Conclusion: A significant alteration in the plasma TAFI antigen levels was detected in acromegaly. Increased plasma TAFI antigen levelsmight aggravate prothrombotic and thrombotic events in patients with acromegaly.